Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Investigating a new Vaccine Against Meningitis B in OXford - VAMBOX

Trial categories: Brain; Immunity; Infection; Vaccines

Sponsoring organisation: University of Oxford

You are invited to take part in a study to investigate a new Vaccine Against Meningitis B in Oxford (VAMBOX).

The study is being run by the Oxford Vaccine Group at the University of Oxford.

If you are 18 to 50 yrs old and are in good health, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience and travel. Participants will receive up to £630.00 if they remain in the study for the entire period. The total study participation time is 12 months.


Neisseria meningitidis is a bacteria that can cause meningitis (infection of the lining of the brain) and septicaemia (blood poisoning). This is a particular problem in infants, children and adolescents. In 2015/2016 in the UK there were 805 documented cases of invasive meningococcal disease (either meningitis or septicaemia) identified, with 43 deaths. Neisseria meningitidis B, or Meningitis B, accounted for 55 percent of these cases.

Study goals

In this study we are testing a new vaccine against Neisseria meningitidis B.

Currently, there are two licensed vaccines against Meningitis B available in the UK, Bexsero® and Trumenba®. Bexsero® is included in the UK routine immunisation schedule, but it commonly causes side effects (fever and pain), requires three injections to establish immunity, and has been deemed to not be cost effective in the UK.

The Oxford Vaccine Group is therefore proposing a new vaccine, which may produce a better immune response, be cheaper and require less doses. In addition, the study will enable the development of reference serum standards against the two meningococcal vaccines, Bexsero® and Trumenba®.

Further information

The Oxford Vaccine Group, University of Oxford, is based in the Centre for Clinical Vaccinology and Tropical Medicine in the Churchill Hospital site. Up to July 2018, the study will be funded by the Medical Research Council under a Developmental Pathway Funding Scheme award. After July 2018 the study will be funded by a National Institute for Health Research (Biomedical Research Centre grant).

If you are interested in finding out more, please visit our website:

where you can register your interest and access the Study Information Booklet.

If you would like any further information regarding the study please contact us on:

Kind regards,

The Oxford Vaccine Group

Study reference: IRAS ID 227641
Ethics reference: 17/SC/0470